iSelect Fund

Harnessing Bioactives for Better Gut Health

Meet Bio Gut Core—Brightseed’s new ingredient clinically proven to strengthen the gut barrier and reduce bloating and abdominal pain within just three weeks. This ready-to-use formulation combines two plant‑derived bioactives discovered by Brightseed’s AI platform. It’s another example of how the ingredients we invest in have tangible health benefits.

Food isn’t just fuel; it’s information that tells our bodies how to function. Brightseed shows how science can unlock nature’s secrets to improve digestive wellness.



Learn more:

Brightseed Debuts Bio Gut Core™, a Low-Dose, Digestive Health Ingredient Clinically Proven to Strengthen Gut Barrier and Reduce Bloating and Abdominal Pain in Just Three Weeks Today, Brightseed announced Bio Gut Core, a ready-to-use bioactive ingredient that delivers clinically-proven gut health benefits in low-dose, versatile ingr...

Drone Data Meets the Field

John Deere has acquired Sentera to bring high-resolution drone imagery and AI‑based w**d mapping into its Operations Center. This integration will allow farmers to convert aerial scouting into real-time decisions that reduce pesticide use, improve yields and boost profitability.

Better data leads to healthier soils and crops. By investing in companies like Sentera, we’re helping create a farming system where technology drives sustainability and food quality.



Read more:

John Deere Acquires Drone Camera Maker to Integrate Aerial Field Scouting Drones equipped with Sentera's tech fly over fields at high speeds to identify the exact location of specific w**ds.

Designing Better Proteins for People & Planet

We’re excited to see Geltor close a new funding round—co‑led by iSelect—bringing its total funding to $137M. With this capital, Geltor will expand its biodesigned polypeptide portfolio into new geographies. The company recently launched a vegan collagen polypeptide in Latin America and received FDA GRAS approval for its Type 21 collagen (PrimaColl).

Geltor uses AI to design animal-free proteins that deliver the performance consumers expect while reducing environmental impact.

Innovative ingredients like these are exactly what our Food Is Health thesis is about: providing better nutrition through sustainable science.

Geltor raises venture capital to fund polypeptide expansion US personal care ingredient maker Geltor has raised fresh funding via an equity financing round led by Miami venture capital outfit Starlight Ventures.

We are excited to announce iSelect Fund’s participation in Geneoscopy’s $105 million Series C funding round. This investment will support the commercialization of Geneoscopy's FDA-approved ColoSense® test for colorectal cancer screening and advance diagnostics for inflammatory bowel disease.

Colorectal cancer rates are rising alarmingly, particularly among younger adults, and it remains the second-leading cause of cancer-related deaths. Early detection through innovative, non-invasive tools like ColoSense® can save countless lives by identifying cancer in its most treatable stages.

Geneoscopy’s platform isolates human RNA from stool samples for accurate detection, with enhanced accessibility through collaborations with Bio-Rad and Labcorp. iSelect Fund is proud to back transformative healthcare solutions like these.

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests - Geneoscopy - Transforming Gastrointestinal Health ST. LOUIS & HERCULES, Calif. – Jan. 8, 2025 – Geneoscopy, Inc., a life sciences company focused on developing diagnostic tests for the advancement of